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There are not so many organisms that are so well studied and researched as 
the bacterium Escherichia coli (E. coli). Since its discovery in 1885, it was used in 
research, and by end of 2018, there are now already 368,071 publications in PubMed 
about E. coli [1]. Figure 1, presenting data about number of publications found in 
PubMed for the search term “Escherichia coli” in the time frame from 1932 to 2018, 
clearly demonstrates the high and still growing research interest in this microbe.
2. The discovery of Escherichia coli
The bacterium E. coli was discovered by the German-Austrian pediatrician 
Dr. Theodor Escherich (1857–1911) in 1885 [2]. He conducted examinations of 
neonate’s meconium and feces of breast-fed infants with the aim to gain insight 
into the development of intestinal “flora.” In preparations of meconium and stool 
samples under the microscope, he observed “slender short rods” of the size of 
1–5 μm in length and 0.3–0.4 μm in width, which he named Bacterium coli commune 
(Figure 2). Further, he cultured these bacteria on agar and blood serum plates, 
where these bacteria grew as white, non-liquefying colonies. He also showed that 
these bacteria slowly cause milk to be clotted, as a result of acid formation, and 
Figure 1. 
Number of publications in PubMed for the search term “Escherichia coli” in the time frame from January 01, 
1932 to December 31, 2018 [1].
The Universe of Escherichia coli
2
demonstrated that these bacteria have fermentative ability. He also performed the 
Gram method of staining and revealed that these bacteria rapidly take color with 
all aniline dyes but lose the color after treatment with potassium iodide and alcohol 
[2]. Later, in 1919, the bacterium was renamed after its discoverer by Castellani and 
Chalmers and became Escherichia coli [3].
Figure 2. 
Escherich’s drawing of the stool bacteria, as seen under light microscope [4]. Panel 1: Preparation of a 
meconium of a 27-hour-old infant. The E. coli as Bacterium coli commune is represented under d. Panel 2: 
Preparation of a stool of a 2-month-old healthy breast-fed child. The E. coli as Bacterium coli commune is 
represented under a and a′.
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3. Characteristics of Escherichia coli
3.1 Basic characteristics
The bacterium E. coli (Figure 3) belongs into the family of Enterobacteriaceae. It 
is a Gram-negative rod-shaped bacterium, non-sporulating, nonmotile or motile by 
peritrichous flagella, chemoorganotrophic, facultative anaerobic, producing acid 
from glucose, catalase positive, oxidase negative, and mesophilic [5].
E. coli is a well-known commensal bacterium that is among the first colonizing 
bacteria of the gut after birth. It is a highly successful competitor in the human gut 
and is comprising the most abundant facultative anaerobe of the human intestinal 
microbiota [7]. As it is a facultative anaerobe, it survives when released to the envi-
ronment and can be spread to new hosts. E. coli is thus an important component of 
the biosphere [8].
Even though E. coli is a well-known commensal bacterium, many pathogenic strains 
of E. coli do exist. Several highly adapted E. coli clones have acquired specific virulence 
factors, which confer an increased ability to adapt to new niches and allow them to 
cause a broad spectrum of disease, and intestinal and also extraintestinal infections [7].
3.2 The E. coli genome
The first complete E. coli genome sequence was the sequence of the K-12 MG1655 
strain of E. coli, published in 1997. The sequenced strain has been maintained as a 
laboratory strain with minimal genetic manipulation, having only been cured of 
the temperate bacteriophage lambda and F plasmid. The published genome has 
4,639,221 base pairs. Protein-coding genes account for 87.8% of the genome, 0.8% 
encodes stable RNAs, and 0.7% consists of noncoding repeats. Eleven percent of the 
genome are involved in regulation of gene expression and also other functions [9]. 
A circular map of the E. coli genome is represented in Figure 4.
The map is based on the K-12 MG1655 sequence data as deposited in GenBank 
(Accession number NC_000913) [10]. The multiplier for the ticks is 1e-6 (1.0 rep-
resents 1,000,000). In blue, the forward genes are shown, in purple the reverse 
genes, tRNA genes in orange, and rRNA genes in red. The map was drawn with 
Figure 3. 
Scanning electron microscopy of a single bacterial E. coli cell adhering to 19-day-old Caco-2 cells [6].
The Universe of Escherichia coli
4
the online tool ClicO FS, available at the Internet site http://www.codoncloud.
com:3000/home [11, 12].
Genomes of pathogenic E. coli strains are general bigger, as the pathogenic 
strains need several special properties, so-called virulence factors. These are 
encoded in the virulence-associated genes (VAGs), which are frequently clustered 
in DNA regions called pathogenicity islands (PAIs) [13]. Often the pathogenic 
strains possess also extrachromosomal DNA elements, i.e., plasmids, that can also 
carry additional VAGs [7]. Some examples of genomes of pathogenic strains in 
comparison with the K-12 MG1655 strain are given in Table 1.
Data in the table are based on data available in the genome database of the National 
Center for Biotechnology Information (Internet site: www.ncbi.nlm.nih.gov) [14].
The most famous E. coli plasmid is the plasmid F (Figure 5). It is the paradigm 
plasmid for plasmid-specified transfer systems, as bacterial conjugation was first 
identified as a function of the F plasmid. Further, this plasmid was used to develop 
many of the genetic techniques commonly used to dissect prokaryotic systems, and 
F product analysis has been central in elucidating the basic mechanisms of plasmid 
replication and transmission [15].
F plasmid has two functional replication regions, RepFIA and RepFIB. The RepFIA 
region is believed to be primarily responsible for the typical replication properties of 
F [16]. The secondary replication region, RepFIB, is independently functional and can 
perform replication in the absence of RepFIA. F plasmid has also remnants of a third 
replication region, RepFIC, whose function was abolished by transposition of Tn1000 
into this replication region [17]. Apart from Tn1000 also insertion sequences IS2 and 
IS3 are carried on F plasmid [16]. The plasmid-specified transfer system is encoded in 
the tra region, starting with the origin of transfer (oriT) [15].
Figure 4. 
Circular map of the E. coli K-12 MG1655 strain.
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3.3 The phylogenetic groups of E. coli
The E. coli species has an extensive genetic substructure and the methods to 
assess the phylogenetic relationship among E. coli strains evolved during the time. 
In the pre-molecular era, the E. coli diversity was studied by serotyping. Serotyping 
studies showed that the somatic (O) antigen, the flagellar (H) antigen, and to a 
lesser extent the capsular (K) antigen are useful in distinguishing E. coli strains 
[19]. The E. coli serotyping is complex—173 O antigens, 80 K antigens, and 56 H 
antigens are known—and the O, K, and H antigens can be found in nature in many 
of the possible combinations. The final number of E. coli serotypes is therefore very 
high, 50,000–100,000 or more [20].






















5.5 5.329 pO157 92.721 85
pOSAK1 3306 3
O7:K1 IAI39 Urinary tract 
infection












5.27 5.081 pG-EA11 1549 1
pAA-EA11 74.217 82
pESBL-EA11 88.544 94
UMN026 Urinary tract 
infection
5.2 5.096 p1ESCUM 122.301 156
p2ESCUM 33.809 49
Table 1. 
Genomes of different E. coli strains.
Figure 5. 
Map of the E. coli F plasmid. The map was drawn based on the complete nucleotide sequence of the F plasmid 
as deposited in GenBank [18].
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The molecular studies of E. coli diversity began with the measurement of varia-
tions in electrophoretic mobility of enzymes derived from different E. coli strains 
[21]. In 1980s the multi-locus enzyme electrophoresis (MLEE) became the common 
technique for the study of bacterial diversity. It was found that E. coli populations 
evolve in a clonal manner, with recombination playing a limited role, and it also 
became clear that genetically distant strains can have the same serotype and that 
closely related strains may have different serotypes [19]. Based on the MLEE stud-
ies of 38 enzyme loci, four major phylogenetic groups among E. coli were found: A, 
B1, B2, and D [22]. Clermont et al. [23] established a method of rapid and simple 
determination of the E. coli phylogenetic groups by a triplex PCR. This genotyping 
method is based on the amplification of a 279 bp fragment of the chuA gene; a 211 bp 
fragment of the yjaA gene; and a 152 bp fragment of TSPE4.C2, a noncoding region 
of the genome. The presence or absence of combinations of these three amplicons is 
used to assign the E. coli to the phylogenetic groups: A, B1, B2, or D (Figure 6).
However, subsequently, on the basis of multi-locus sequence typing and 
complete genome data, additional E. coli phylogenetic groups were recognized  
[24, 25]. The number of defined phylogenetic groups thus rose to eight (A, B1, 
B2, C, D, E, F that belongs to E. coli sensu stricto, and the eighth—the Escherichia 
cryptic clade I). Clermont et al. [26] thus revised their method to encompass the 
newly described phylogenetic groups. To enable identification of the F phyloge-
netic group, the new extended PCR phylotyping method employs an additional 
gene target, arpA, which serves also as an internal control for DNA quality. Thus, 
the revised PCR method is based on a quadruplex PCR, and if required, addi-
tional single PCR reactions are employed to distinguish between E and clade I, A 
or C, and D or E phylo-group [26] (Figure 7).
Two collections of human fecal isolates were screened using the quadruplex 
phylo-group assignment method demonstrating that 12.8% of E. coli isolates 
belonged to the newly described phylo-groups C, E, F, and clade I and that 
strains assigned to phylo-groups A and D by the triplex method are worth to 
be retested by the quadruplex method, as it is likely that they are going to be 
reclassified [26]. Logue et al. [27] performed a comparative analysis of phylo-
genetic assignment of human and avian extraintestinal pathogenic (ExPEC) 
and fecal commensal E. coli (FEC) strains and showed that a total 13.05% of 
studied human E. coli strains and 40.49% of avian E. coli strains had to be 
Figure 6. 
Dichotomous decision tree to determine the phylogenetic group by the Clermont triplex PCR method [23].
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reclassified. Another study using human E. coli strains isolated from skin and 
soft-tissue infections and fecal E. coli strains from healthy humans and also 
avian and brown bear fecal strains revealed that 27.60% of human, 23.33% 
of avian, and 70.93% of brown bear strains had to be reclassified. Moreover, 
a high number (12.22%) of reclassifications from the previous phylo-groups 
to the non-typeable (NT) group were observed among the avian fecal strains 
of this study. Further, a survey performed on other published data by Starčič 
Erjavec et al. [28] showed that also a number of other studies report occurrence 
of NT strains by the quadruplex method, for example, a study including 140 
uropathogenic E. coli strains from Iran reported 27.14% of NT strains [29]. 
These data emphasizes that there is a need to search for more E. coli strains 
from novel environments (new hosts in not yet explored geographic regions) 
and to revise the PCR phylotyping method again in order to type these NT 
strains.
3.4 The commensal E. coli
As E. coli is a facultative anaerobe, and among the first gut colonizers, these bac-
teria help to establish the anaerobic environment of the gut that enables the further 
colonization of the gut by anaerobic bacteria [30]. After the E. coli colonization, 
usually the host and E. coli coexist in mutual benefit for decades [7]. E. coli gets 
“food and shelter,” and the host benefits due to the E. coli vitamin K production and 
the so-called colonization resistance. Colonization resistance is the phenomenon 
of protection against colonization by pathogenic bacteria, including pathogenic E. 
coli [31]. The niche of the commensal E. coli is the mucous layer of the colon [7]. On 
average five different commensal E. coli strains colonize a human host at any given 
time [32]. As host and the E. coli profits from their association, these E. coli could be 
also designated as mutualistic E. coli.
3.5 The pathogenic E. coli
E. coli is also a medically important species, as it is involved in many different 
types of infections. Two major groups of pathogenic E. coli exists: the intestinal 
Figure 7. 
Dichotomous decision tree to determine the phylogenetic group by the Clermont quadruplex PCR method [26].
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pathogenic E. coli (IPEC), associated with infections of the gastrointestinal 
tract, and the extraintestinal pathogenic E. coli (ExPEC), associated with infec-
tions of extraintestinal anatomic sites [7]. The medical diversity of this species is 
nicely exhibited by its classification of pathogenic E. coli (Figure 8), the so-called 
E. coli pathotypes.
The versatility of pathogenic E. coli strains depends on their genetic 
makeup, on the presence of so-called virulence genes, and possession of such 
genes distinguishes pathogenic from nonpathogenic bacteria [34]. Virulence 
factors help bacteria to (1) invade the host, (2) cause disease, and (3) evade host 
defenses [35].
3.5.1 Adhesins and invasins
Once a bacterium reaches the host surface, in order to colonize, it must adhere to 
host cells. For this purpose bacteria have different fimbrial and afimbrial adhesins. 
Fimbrial adhesins are rod-shaped protein structures, which consists primarily of an 
ordered array of single protein subunits, which build a long cylindrical structure. 
At the top, there are proteins, adhesins, which mediate the adherence to the host’s 
molecules. A fimbrial adhesin is thus a structure that extends outward from the 
bacterial surface and establishes the contact between the bacterial surface and 
the surface of the host cells. Afimbrial adhesins are surface proteins important for 
tighter binding of bacteria to host cells. Some bacteria have evolved mechanisms 
for entering nonphagocytic host cells. Bacterial surface proteins that provoke actin 
rearrangements and thereby incite the phagocytic ingestion of the bacterium by 
host cells are called invasins [36]. The most known E. coli adhesins and invasins are 
presented in Table 2.
Figure 8. 
Classification of pathogenic E. coli, based on Roy et al. [33]. The IPEC are also designated as 
diarrheagenic E. coli (DEC)—Although not all of the subtypes in this group necessarily cause diarrhea. 
STEC that cause hemorrhagic colitis and/or the hemolytic uremic syndrome are called EHEC—For 
enterohemorrhagic E. coli. Among ExPEC also strains associated with pneumonia, skin and soft-tissues, 
and infections of many other extraintestinal anatomic sites are present, though they are not yet established 
as separate pathotypes.
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3.5.2 Iron acquisition mechanisms
Iron is essential for bacterial growth, but iron concentrations in nature are 
generally quite low, particularly low in host organism. To survive in the host organ-
ism, bacteria must have some mechanisms for acquiring iron. The best studied type 
of bacterial iron acquisition is the siderophores. These are low-molecular-weight 
compounds that chelate iron with very high affinity [36]. The most known E. coli 
iron uptake systems are presented in Table 3.
3.5.3 Systems to evade host immune response
The healthy host usually has multilayered defenses that prevent the establish-
ment of bacterial infection. Among the most effective of these defenses is the 
immune response. However, bacteria have evolved systems to avoid, subvert, or 
circumvent innate host defenses and to evade acquired specific immune responses 
of the host [34]. A capsule is a loose, relatively unstructured network of polymers 
that covers the surface of a bacterium. The role of capsules in bacterial virulence is 
to protect bacteria from the host’s inflammatory response [36]. Further, increased 
serum resistance is often found among pathogenic bacteria, especially those 
associated with systemic infections [36]. Serum resistance is the ability to prevent 
complement activation on the bacterial cell surface and to inhibit insertion of the 
membrane attack complex into the bacterial membrane [34]. The feature is often 
based on the modifications in lipopolysaccharide (LPS), which can be of two types: 
either attachment of sialic acid to LPS O antigen or changes in the LPS O antigen 
side chain [36]. However, other proteins can also be implicated in increased serum 
resistance; for example, the TraT protein of the surface exclusion complex involved 
in conjugation [37]. Another important protein of pathogenic E. coli is the Toll/
interleukin-1 receptor domain-containing protein (Tcp) that interferes with the 
TLR signaling system of the innate immunity [38]. The most known E. coli systems 
to evade host immune response are presented in Table 4.
Adhesin/invasin Most commonly tested virulence 
(associated) genes
Type 1 fimbriae (Fim) fimH
P fimbriae (Pap/Prf) papC, papG
S/F1C fimbriae (Sfa/Foc) sfa/focDE
N-Acetyl-d-glucosamine-specific fimbriae (Gaf) gafD
M-Agglutinin (Bma) bmaE
Bifunctional enterobactin receptor/adhesin (Iha) iha
Afimbrial adhesin (Afa) afa/draBC
Invasion of brain endothelium (IbeA) ibeA
Colonization factor antigen I (CFA/I) cfaB
Bundle-forming pili (BFP) bfpA
Intimin eaeA
Aggregative adherence fimbriae (AAF/I) aaf/I
Table 2. 
Typical adhesins and invasins of pathogenic E. coli strains.
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3.5.4 Toxins
Toxins are the virulence factors that damage the host. Exotoxins are toxic bacte-
rial proteins that are excreted into the medium by growing bacteria or localized in 
the bacterial cytoplasm or periplasm and released during bacterial lysis. Exotoxins 
vary considerably in their activities and the target host cell types [36]. The most 
known E. coli toxins (exotoxins) are presented in Table 5.
Host immunity evading system Most commonly tested virulence 
(associated) genes
Group II capsule including K1 and K5 capsules kpsMT II
Conjugal transfer surface exclusion protein (TraT) traT
Outer membrane protease T (OmpT) ompT, APEC-ompT
Increased serum survival (Iss) iss




Typical host immunity evading systems of pathogenic E. coli strains.
Iron uptake system Most commonly tested virulence 
(associated) genes
Aerobactin (Iuc) iucD, iutA
Yersiniabactin (Ybt) fyuA, irp2
Salmochelin (Iro) iroCD, iroN
Siderophore receptor IreA ireA
Temperature sensitive hemagglutinin (Tsh)—in birds, Hemoglobin 
protease (Hbp)—in humans
tsh, hbp
Periplasmic iron binding protein (SitA) sitA
Ferrichrome-iron receptor (Fhu) fhuA
Table 3. 
Typical iron uptake systems of pathogenic E. coli strains.
Toxins Most commonly tested virulence 
(associated) genes
alpha-Hemolysin (HlyA) hlyA
Cytotoxic necrotizing factor 1 (CNF-1) cnf1
Cytolethal distending toxin IV (CDT 1) cdtB
Uropathogenic specific protein (Usp) usp
Colibactin (Clb) clbAQ
Serine protease autotransporters Sat, Pic sat, picU
Heat-stable toxins (STa, STb) stIa/stIb
Heat-labile toxin I (LTI), heat-labile toxin II (LTII) eltI, eltIIa
Shiga toxin 1 (Stx1), Shiga toxin 2 (Stx2) stxI, stxII
EHEC hemolysin (Ehx) ehxA
Low-MW heat-stable toxin (EAST1) astA
Table 5. 
Typical toxins (exotoxins) of pathogenic E. coli strains.
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However, E. coli possess also an endotoxin, namely, the lipopolysaccharide, 
which is an integral component of the outer membrane of Gram-negative bacteria. 
The lipid portion (lipid A) is embedded in the outer membrane, with the core and 
O antigen portions extending outward from the bacterial surface. Lipid A is the 
toxic portion of the molecule, and it exerts its effects only when bacteria are lysed. 
The toxicity of lipid A resides primarily in its ability to activate, complement, and 
stimulate the release of bioactive host proteins, such as cytokines [36].
3.6 The antibiotic-resistant E. coli
Antibiotics are low-molecular-weight compounds that kill or inhibit growth 
of bacteria [36]. Antibiotic treatment is one of the main approaches of modern 
medicine to combat bacterial infections, including also E. coli infections [39]. 
However, bacteria evolved different mechanisms that confer resistances to anti-
biotics. Resistant bacteria are able to either (i) modify/degrade the antibiotic, (ii) 
actively transport the antibiotic out of the cell or prevent its intake, (iii) sequester 
the antibiotic by special proteins, or (iv) modify, bypass, or protect the target [40]. 
The emergence, spread, and persistence of resistant and even multidrug-resistant 
(MDR) bacteria or “superbugs”, also among E. coli, are now posing a serious global 
health threat of growing concern [39]. The antimicrobial resistance surveillance 
data of European Centre for Disease Prevention and Control (ECDC) also showed 
the increase in antibiotic resistance among invasive E. coli isolates (Figure 9).
The mechanisms of resistance to antibiotics are encoded in resistance genes. A 
list of typical E. coli resistance genes is given in Table 6.
As many of the resistance genes are encoded on conjugative plasmids or conjuga-
tive transposons, they are easily transferred between different bacteria and hence 
spread in the population [36].
3.7 The bacteriocinogenic E. coli
Bacteriocins are ribosomally synthesized, proteinaceous substances that 
inhibit the growth of closely related species through numerous mechanisms [51]. 
Figure 9. 
Prevalence of invasive E. coli isolates with antimicrobial resistance to aminopenicillins, fluoroquinolones, 
third-generation cephalosporins, aminoglycosides, and carbapenems—the population weighted mean EU/EEA 
is shown. The prevalence of antimicrobial resistance to carbapenems in 2009 and 2011 was 0%, in 2012 <0.1%, 
in 2013 and 2015 0.2%, and in 2014, 2016, and 2017 0.1% [41–49].
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They are a heterogeneous group of particles with different morphological and 
biochemical entities. They range from a simple protein to a high molecular weight 
complex [52]. The bacteriocins with molecular masses below 10 kDa are desig-
nated as microcins [53]. Bacteriocins are potent toxins that are usually produced 
during stressful conditions and result in the rapid elimination of neighboring 
bacterial cells that are not immune or resistant to their effect. The killing is 
exhibited after adsorption to specific receptors located on the external surface 
of sensitive bacteria, by one of the three primary mechanisms: forming chan-
nels in the cytoplasmic membrane, degrading cellular DNA/RNA, or inhibiting 
protein synthesis. Because of their narrow range of activity, it has been proposed 
that the primary role of bacteriocins is to mediate intraspecific, or population 
level, interactions [54]. The genetic determinants of most of the bacteriocins 
are located on the plasmids, apart from few, which are chromosomally encoded 
[52]. Bacteriocins of E. coli are usually called colicins. A relatively high frequency 
of colicin-encoding plasmids is found in isolates of pathogenic E. coli [55], for 
example, ~80% of O157:H7 enterohemorrhagic E. coli strains studied by Bradley 
and Howard were colicinogenic [56]. Especially microcins have been associated 
with pathogenic strains [54]. In a collection of E. coli strains isolated from skin 
and soft-tissue infections, 55% of strains possessed microcin M, and 43% pos-
sessed microcin H47 [57]. Further, colicin insensitivity among these strains cor-
related with a higher prevalence of extraintestinal virulence factors [58]. Typical 
E. coli bacteriocins, their receptors, translocation systems, and mode of action are 
given in Table 7.
Resistance gene(s) Antibiotic class Resistance to
strA [aph(3′)-Ib], strB [aph(6′)-Id] Aminoglycosides STR
aadA1, aadA2, aadA5, aadA7, aadA24 Aminoglycosides STR
aph(3′)-Ia Aminoglycosides KAN
aac(3′)-VI, aac(3′)-IId Aminoglycosides GEN
blaTEM-1 β-Lactams AMP
blaOXA-1 β-Lactams AMP
blaCMY-2 β-Lactams AMC, AMP, CRO, FOX, TIO
ampC β-Lactams AMC, AMP, FOX
sul1, sul2, sul3 Folate synthesis inhibitors FIS




catA1, catB3 Phenicols CHL
qnrB2, qnrB6, qnrS2 Quinolones NAL, CIP
tet(A), tet(B), tet(C), tet(D), tet(M) Tetracyclines TET
STR, streptomycin; KAN, kanamycin; GEN, gentamicin; AMP, ampicillin; AMC, amoxicillin/clavulanic acid; 
CRO, ceftriaxone; FOX, cefoxitin; TIO, ceftiofur; FIS, sulfisoxazole; SXT, trimethoprim/sulfamethoxazole; AZM, 
azithromycin; CHL, chloramphenicol; NAL, nalidixic acid; CIP, ciprofloxacin; TET, tetracycline [50].
Table 6. 
Typical E. coli resistance genes.
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3.8 The probiotic E. coli
Probiotics are live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host. Probiotic bacteria act via a 
variety of means, including modulation of immune function, production of 
organic acids and antimicrobial compounds, interaction with resident micro-
biota, interfacing with the host, improving the gut barrier integrity, and 
enzyme formation [61]. Several E. coli strains were recognized as good and 
effective probiotics and are now used in drugs (see Table 8). The probiotic 
E. coli are applied to a variety of human conditions, including intestinal 
bowel diseases and diarrhea. Further it was shown that colonization of new-
borns led to reduced disease rates, lower incidence of allergies, and reduced 
mortality [62].
E. coli Nissle 1917 is nowadays often used as a reference strain or model 
microorganism in experimental biomedical studies, including recombinant 
manipulations of the strain in order to construct derivatives with novel proper-
ties [64]. One such example is the strain ŽP, which is a genetically modified 
Nissle 1917 possessing a bacterial conjugation-based “kill”-“anti-kill” antimi-
crobial system—a conjugative plasmid carrying the “kill” gene (colicin ColE7 
activity gene) and a chromosomally encoded “anti-kill” gene (ColE7 immunity 
gene). Hence, in the process of conjugation, the conjugative plasmid transfers 
the “kill” gene into a recipient cell, where it is expressed and the recipient 
killed [65, 66].
Bacteriocin Receptor Translocation system Mode of action
ColA BtuB Tol Ion channel
ColB FepA Ton Ion channel
ColD FepA Ton Stops translation
ColE1 BtuB Tol Ion channel
ColE2 BtuB Tol DNA-endonuclease
ColE3 BtuB Tol rRNA-endonuclease
ColE4 BtuB Tol rRNA-endonuclease
ColE5 BtuB Tol Stops translation
ColE6 BtuB Tol rRNA-endonuclease
ColE7 BtuB Tol DNA-endonuclease
ColE8-J BtuB Tol DNA-endonuclease
ColIa Cir Ton Ion channel
ColIb Cir Ton Ion channel
ColK Tsx Tol Ion channel
ColM FhuA Ton Inhibition of peptidoglycan synthesis
ColN OmpF Tol Ion channel
ColS4 OmpW Tol Ion channel
Table 7. 
Typical E. coli bacteriocins, their receptor, translocation system, and mode of action [59, 60].
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3.9 The “workhorse” E. coli
E. coli is known for its fast growing rate in chemically defined media and exten-
sive molecular tools available for different purposes. All these make it an important 
model organism, which is also called the “workhorse” of molecular biology. Even 
though E. coli lacks many interesting features appreciated in biotechnology, such 
as growing at extreme temperatures or pH and the capacity to degrade toxic com-
pounds, pollutants, or difficult to degrade polymers, it is much used in biotechnol-
ogy also [67]. In Table 9 contributions of E. coli to biology, medicine, and industry 
are listed.
The following recombinant pharmaceuticals were set up to be in vivo syn-
thesized in E. coli: insulin, interleukin-2, human interferon-β, erythropoietin, 
human growth hormone, human blood clotting factors, pegloticase,  
taxol, and certolizumab. Further, E. coli is also used to produce biofuels 
and industrial chemicals such as phenol, ethanol, mannitol, and a variety of 
others [68].
Drug name Mutaflor Symbioflor 2 Colinfant newborn
E. coli strain E. coli Nissle 1917 strain Six different E. 
coli strains (G1/2, 
G3/10, G4/9, G5, G6/7, 
and G8)
E. coli A0 34/86 strain
Product Capsules Suspension Powder for preparation 
of per oral solution

















of the used 
strain(s)
1915 1954 Data not available
Serotype 06:K5:H1 Variable including 
035,129, 0:169, rough, 
all H–
083:K24:H31
Plasmid content 2 cryptic plasmids 12 plasmids No plasmids
Microcin 
production
Microcin M, H47 Microcin S Data not available
Motility Motile (flagella present) Nonmotile (flagella 
absent)
Data not available











Probiotic E. coli drugs [62, 63].
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4. Conclusion
To conclude, E. coli is a truly versatile microorganism possessing many facets—it 
is a well-known commensal bacterium, but some strains can be also pathogenic, 
even causing mortality, especially if the pathogenic strain acquired multiple 
resistance genes. However used as a probiotic it can improve health and in it can be 
Contribution Authors Year
Molecular biology, physiology, and genetics
Elucidation of the genetic code Crick FH, Barnett L, Brenner S, and 
Watts-Tobin RJ
1961
DNA replication Lehman IR, Bessman MJ, Simms ES, 
and Kornberg A
1958
Transcription Stevens A 1960
Life cycle of lytic bacteriophages Ellis EL and Delbrück M 1939
Gene regulation of the lac operon Jacob F and Monod J 1961
Gene regulation of the ara operon Englesberg E, Irr J, Power J, and Lee N 1965
Discovery of restriction enzymes Linn S and Arber W 1968
Identification of genes controlling antimicrobial 
drug tolerance in stationary phase
Hu Y and Coates AR 2005
Role of global regulators and nucleotide 
metabolism in antibiotic tolerance
Hansen S, Lewis K, and Vulić M 2008
Metabolic control of persister formation Amato SM, Orman MA, and 
Brynildsen MP
2013
Swarming motility behavior Harshey RM and Matsuyama T. 1994
Elucidation of the structure and function of ATP 
synthase
Capaldi RA, Schulenberg B, Murray J, 
and Aggeler R
2000
Conjugal DNA transfer Tatum EL and Lederberg J 1947
Evolution
Random nature of mutation Luria SE and Delbrück M 1943
Relationship between genomic evolution and 
adaptation
Barrick JE, Yu DS, Yoon SH, Oh TK, 
Schneider D, Lenski RE, and Kim JF
2009
Role of adaption, chance, and history in evolution Travisano M, Mongold JA, Bennet AF, 
and Lenski RE
1995
Adaptive mutation Cairns J, Overbaugh J, and Miller S 1988
Role of historical contingency in evolution Blount ZD, Borland CZ, and Lenski RE 2008
Origin of novel traits Blount ZD, Barrick JE, Davidson CJ, 
and Lenski RE
2012
Long-term fitness trajectories Wiser MJ, Ribeck N, and Lenski RE 2013
Effect of sexual recombination on adaptation Cooper TF 2007
Predator-prey interactions (bacteriophage) Chao L and Levin BR 1977
Genetic engineering and biotechnology
Molecular cloning and recombinant DNA Cohen S, Chang A, Boyer H, and 
Helling R
1973
Generating precise deletions and insertions Link AJ, Phillips D, and Church GM 1997




Contributions of E. coli to biology, medicine, and industry [68–70].
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employed as a good working “workhorse” in the laboratory as well as in biotechno-
logical settings. The differentiation between commensal and pathogenic strains is 
not easy, as among the healthy gut microbiota pathogenic strains are hidden, and 
also commensal strains can become pathogenic due to horizontal gene transfer of 
mobile genetic elements possessing virulence genes [71]. Even though E. coli has 
been the object of research now for already more than 100 years, its versatility war-
rants new possibilities for investigation also in the future.
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